Latest Breaking News On - Kalvista pharmaceuticals company profile get rating - Page 1 : comparemela.com

Equities analysts expect KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Get Rating) to report earnings per share of ($1.01) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for KalVista Pharmaceuticals’ earnings, with estimates ranging from ($1.19) to ($0.81). KalVista Pharmaceuticals posted earnings per share of ($0.65) during the same quarter last […]

Thomas andrew crockettSecurities exchange commissionLife insurance coZacks investment researchCapital partnersKalvista pharmaceuticals company profile get ratingNeedham companyKalvista pharmaceuticals incJpmorgan chase coKalvista pharmaceuticalsRoyal bankGet ratingKalvista pharmaceuticalVista pharmaceuticalsInvestment researchRoth capital